TBC1D23

Across TCGA pan-cancer cohorts, TBC1D23 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated TBC1D23 data layer compared with 23 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher TBC1D23 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TBC1D23 expression acts as an unfavorable survival marker.

COAD, STAD, and PRAD are the cancer types where TBC1D23 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	OS	Median	II,III,IV	0.297	0.789	<.001	18	view →
STAD	OS	Median	All	0.003	0.667	<.001	18	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LUSC	DFS	Median	All	0.132	0.797	<.001	6	view →
SKCM	DFS	Median	III,IV	0.015	0.648	<.001	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

TBC1D23–COAD (OS)

Open the COAD breakdown →